Skip to search formSkip to main contentSkip to account menu

GV 150526A

Known as: GV-150526A, GV150526, GV150526A 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Evaluation of Direct Transport Pathways of Glycine Receptor Antagonists and an Angiotensin Antagonist from the Nasal Cavity to the Central Nervous System in the Rat Model
PurposeThe aim of this study was to investigate and quantify drug movement to the brain via the neuro-olfactory system after… 
Highly Cited
2006
Highly Cited
2006
Effect of the Glycine Antagonist Gavestinel on Cerebral Infarcts in Acute Stroke Patients, a Randomized Placebo-Controlled Trial: The GAIN MRI Substudy
Background and Purpose: Gavestinel, GV150526, is a selective antagonist at the glycine site of the N-methyl-D-aspartate receptor… 
Highly Cited
2002
Highly Cited
2002
Glutamate AMPA Receptor Antagonist Treatment for Ischaemic Stroke
SUMMARY During cerebral ischaemia, glutamate is released in supraphysiological amounts and is toxic to brain tissue. This… 
Highly Cited
2001
Highly Cited
2001
Glycine Antagonist (GV150526) in Acute Stroke: A Multicentre, Double-Blind Placebo-Controlled Phase II Trial
GV150526 is a novel glycine antagonist at the NMDA receptor complex. It is a potent neuroprotective agent in animal models of… 
Highly Cited
1999
Highly Cited
1999
Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke.
BACKGROUND AND PURPOSE GV150526 is a novel glycine site antagonist at the N-methyl-D-aspartate receptor complex. It is a potent… 
1999
1999
Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia.
A series of analogues of the indole-2-carboxylate GV150526, currently in clinical trials as a potential neuroprotective agent for… 
1999
1999
First Time in Human for GV196771: Interspecies Scaling Applied on Dose Selection
The utility of interspecies scaling in early drug development has been extensively debated. The authors discuss the dose… 
1998
1998
IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF GV150526, A NOVEL GLYCINE ANTAGONIST AS A POTENT NEUROPROTECTIVE AGENT
Highly Cited
1997
Highly Cited
1997
The Glycine Antagonist GV150526 Protects Somatosensory Evoked Potentials and Reduces the Infarct Area in the MCAo Model of Focal Ischemia in the Rat
The neuroprotective activity of the novel, selective glycine antagonist GV150526 was assessed in the middle artery occlusion… 
1997
1997
N-methyl-D-aspartate antagonists for stroke and head trauma.
The N-methyl-D-aspartate (NMDA) receptor is a ligand-gated ion channel which is widely distributed in the central nervous system… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)